Opinion
Video
Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice
Author(s):
Key Takeaways
- Dermatologists' comfort with JAK inhibitors is influenced by familiarity and patient-specific factors, affecting their willingness to switch treatments.
- Switching from biologics to JAK inhibitors is determined by treatment response, side effects, and patient preferences.
Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.
EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis
EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis
EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients
EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis
EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice
EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis
EP: 7.Speed of Itch Relief in Atopic Dermatitis
EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis
EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis
EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data
Now Viewing
EP: 11.Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice
Video content above is prompted by the following:
- How would you rate dermatologists’ comfort in switching to a JAK inhibitor?
- How often do you have to switch patients from biologics to JAK inhibitors?
- What is your treatment strategy for this patient population?
Related Videos
Related Content
